## Nobel Biocare

## PRESS RELEASE

## **Nobel Biocare Annual General Meeting 2002**

The Annual General Meeting on April 24, 2001, approved a dividend of SEK 3.00 or a total of SEK 76,065,000. The record day for this dividend will be 29 April 2002. Payment is expected to be made by VPC AB (the Swedish Securities Registration Centre) on 3 May 2002.

The following board members were re-elected: Ernst Thomke, Ernst Zaengerle, Jan Kvarnström and Jan Ekberg. Hans-Jörg Graf was elected as new board member. Heliane Canepa had declined re-election as she is the CEO and President of the company.

KPMG Bohlins AB with Thomas Thiel as main auditor was elected.

The remuneration to the board remains unchanged: SEK 1,022,500.

At the board meeting following the election, Ernst Thomke was elected as Chairman of the Board.

The interim report for the first quarter was published 24 April 2002.

The interim report for the first six months will be issued 14 August 2002 and the interim report relating to the first nine months will be published 23 October 2002.

## Settlement

A settlement has been made in the arbitration process with the former president of the company regarding his severance salary. The settlement is within the provisions made.

Gothenburg, 25 April 2002

**NOBEL BIOCARE AB** 

For further information please contact:

Micaela Ahlberg, General Counsel, telephone +46 31 81 88 29 Gunilla Ekholtz, Investor Relations Officer, telephone +46 31 81 88 36 \_\_\_\_\_

\_\_\_\_\_

**Nobel Biocare** is an innovative, medical devices company, whose core business comprises dental implants and dental prosthetics. The company's product systems for dental implants, Brånemark System<sup>®</sup> and Steri-Oss<sup>®</sup>/Replace<sup>™</sup>, are world leaders and have a global market share of 38%.

The company's other product line, Procera®, is a unique, IT-based process for the industrial production

of dental prosthetics. The system has been launched in more than 35 countries.

Nobel Biocare has around 1 300 employees and in 2001 sales totaled SEK 2 663 million. The company's headquarters are located in Gothenburg, Sweden, while production takes place in Sweden and the US. Nobel Biocare has its own sales companies in 26 countries. **www.nobelbiocare.com** 

Nobel Biocare AB, Box 5190, SE-402 26 Gothenburg, Sweden. Tel +46 31-81 88 00.